Treatment and response status in newly diagnosed ENKTL patients
| Treatment (n) | Chemotherapeutic agents (n) | Regimens (n) | CR (n) | PR (n) | SD (n) | PD (n) | NE (n) | ORR (%) |
|---|---|---|---|---|---|---|---|---|
| CT+RT (92) | Anthracycline-based (22) | CHOP-like (9) | 2 | 2 | 1 | 3 | 1 | 57.9 |
| CHOPE-like (13) | 6 | 1 | 1 | 3 | 2 | |||
| Asparaginase-containing (38) | P-Gemox (25) | 18 | 5 | 0 | 2 | 0 | 89.5 | |
| SMILE (5) | 3 | 1 | 1 | 0 | 0 | |||
| CHOP-L/CHOPE-L (6) | 2 | 3 | 0 | 1 | 0 | |||
| DDGP (2) | 1 | 1 | 0 | 0 | 0 | |||
| Gemcitabine combined with platinum (18) | Gemox (6) | 2 | 1 | 1 | 2 | 0 | 70.6 | |
| GDP (10) | 5 | 2 | 1 | 1 | 1 | |||
| GP (2) | 2 | 0 | 0 | 0 | 0 | |||
| Other (14) | GNE (4) | 0 | 1 | 0 | 2 | 1 | 63.6 | |
| DNCE/DICE (5) | 1 | 1 | 1 | 0 | 2 | |||
| Others (5) | 3 | 1 | 0 | 1 | 0 | |||
| CT alone (33) | Anthracycline-based (5) | CHOP-like (4) | 0 | 1 | 0 | 3 | 0 | 20.0 |
| CHOPE-like (1) | 0 | 0 | 0 | 1 | 0 | |||
| Asparaginase-containing (18) | P-Gemox (13) | 2 | 4 | 1 | 4 | 2 | 46.7 | |
| SMILE (1) | 0 | 0 | 0 | 1 | 0 | |||
| CHOP-L/CHOPE-L (3) | 0 | 1 | 0 | 1 | 1 | |||
| Pegaspargase + gemcitabine (1) | 0 | 0 | 0 | 1 | 0 | |||
| Gemcitabine combined with platinum (3) | Gemox (2) | 0 | 2 | 0 | 0 | 0 | - | |
| GDP (1) | 0 | 0 | 0 | 0 | 1 | |||
| Other (7) | - | 1 | 2 | 0 | 4 | 0 | 42.9 | |
| RT alone (4) | - | - | 0 | 2 | 1 | 1 | 0 | 50.0 |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOPE, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide; P-Gemox, pegaspargase, gemcitabine, and oxaliplatin; SMILE, dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; DDGP, dexamethasone, gemcitabine, and cisplatin, pegaspargase; DNCE, dexamethasone, navelbine, cisplatin, and etoposide; DICE, dexamethasone, ifosfamide, cisplatin, and etoposide; GNE, gemcitabine, navelbine, and epirubicin; GP, gemcitabine, platinum; CT, chemotherapy; RT, radiotherapy; NE, not evaluated.